Status:
RECRUITING
Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Lead Sponsor:
Tanta University
Collaborating Sponsors:
Prof. Sahar Kamal Hegazy,Head of Clinical Pharmacy Department,Faculty of Pharmacy,Tanta University
Dr. Raed Ahmed Abdel-Maboud,Lecturer of neurology,Faculty of Medicine,Tanta University
Conditions:
Parkinson Disease
Eligibility:
All Genders
45-65 years
Phase:
PHASE2
Brief Summary
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α...
Eligibility Criteria
Inclusion
- Age between 45 and 65 years old
- Both sexes
- Patients with Parkinson's disease on dopamine replacement therapy
- Modified Hoehn and Yahr stage, MHY 1-4 (29)
Exclusion
- Subjects \< 18 years of age
- Pregnant or breastfeeding women
- Suspected hypersensitivity to silymarin or multivitamins
- Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy)
- Subjects with morbid obesity, i.e., a Body Mass Index (BMI) \> 40
- Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)\>7%
- Current use of Silymarin or recent use within the past two weeks.
- Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.
Key Trial Info
Start Date :
May 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07001150
Start Date
May 10 2025
End Date
May 30 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta Hospital for Mental Health
Tanta, Tanta, Qism 2, Egypt, 31511